Günther M, Stark K, Neuhaus R, Reinke P, Schröder K, Bienzle U
Institute of Tropical Medicine, Department of Surgery, Charité, Humboldt University of Berlin, Centre for Hemodialysis, Germany.
Transplantation. 2001 Feb 15;71(3):477-9. doi: 10.1097/00007890-200102150-00023.
Hepatitis A vaccine is safe and achieves good seroconversion rates in liver (LTX) and renal (RTX) transplant recipients.
A study was performed to determine the anti-hepatitis A virus (HAV) antibody decline in LTX and RTX patients, and in healthy controls who have been immunized with two doses of hepatitis A vaccine.
LTX and RTX patients had a satisfactory seroconversion rate after complete immunisation. However, 2 years later they had experienced a much more rapid antibody decline than controls, and only 59% of LTX and 26% of RTX seroconverters showed titres above the cut-off level defined as protective.
Patients on immunosuppressive therapy may not be adequately protected against hepatitis A a few years after vaccination and alternative vaccination schemes may have to be considered.
甲型肝炎疫苗在肝移植（LTX）和肾移植（RTX）受者中是安全的，并且血清转化率良好。
进行了一项研究，以确定肝移植和肾移植患者以及接受两剂甲型肝炎疫苗免疫的健康对照者体内抗甲型肝炎病毒（HAV）抗体的下降情况。
肝移植和肾移植患者在完全免疫后血清转化率令人满意。然而，2年后，他们的抗体下降速度比对照组快得多，只有59%的肝移植血清转化者和26%的肾移植血清转化者的抗体滴度高于定义为具有保护作用的临界水平。
免疫抑制治疗的患者在接种疫苗几年后可能未得到充分的甲型肝炎防护，可能需要考虑替代的疫苗接种方案。
